Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Policy / Regulatory

China’s NMPA Proposes Sweeping Reforms to Medical Device E-Commerce with New Draft Regulations

Fineline Cube Jul 29, 2026
Company Drug

CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor

Fineline Cube Jul 28, 2026
Company Drug

Hengrui’s Tissue Factor-Targeting ADC SHR-4375 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Jul 28, 2026
Company Deals

Specialised Therapeutics to Commercialize Akeso’s PD-1 Inhibitor Penpulimab in APAC

Fineline Cube Apr 12, 2023

Singapore-based Specialised Therapeutics Asia Pte Ltd (ST) has been appointed to handle the commercialization of...

Company

Legend Biotech Appoints Dr. Mythili Koneru as Chief Medical Officer to Lead Clinical Development

Fineline Cube Apr 12, 2023

China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced the appointment of Dr. Mythili Koneru as...

Company Drug

Luye Pharma’s Bevacizumab Biosimilar Accepted for Review in Brazil by ANVISA

Fineline Cube Apr 12, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that the market approval filing for its...

Policy / Regulatory

Round 8 VBP Tender Results: RMB 3.775 Billion Awarded Across 152 Manufacturers

Fineline Cube Apr 12, 2023

The official results of Round 8 of China’s national Volume-Based Procurement (VBP) tender program have...

Company Drug

Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE

Fineline Cube Apr 12, 2023

The Center for Drug Evaluation (CDE) website has indicated that Huahui Health’s HH-003, Boehringer Ingelheim’s...

Company Drug

Bristol-Myers Squibb Launches Zeposia in China for Multiple Sclerosis Treatment

Fineline Cube Apr 11, 2023

Global pharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced the market launch in China...

Policy / Regulatory

Hubei Implements Inter-Provincial VBP Tender Results for Pacemakers

Fineline Cube Apr 11, 2023

The Hubei provincial Drug and Instrument Procurement Platform has issued a notice regarding the implementation...

Company Drug

Zelgen Biopharmaceuticals’ ZG006 Earns FDA Approval for Small-Cell Lung Cancer Trial

Fineline Cube Apr 11, 2023

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical trial approval from...

Company Drug

JW Therapeutics’ Carteyva Receives NMPA Approval for Moderate-to-Severe SLE Clinical Trial

Fineline Cube Apr 11, 2023

China-based JW Therapeutics (HKG: 2126) has announced receiving tacit clinical trial approval from the National...

Company Deals Digital

Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China

Fineline Cube Apr 11, 2023

China-based Hua Medicine (HKG: 2552) has announced a sales and distribution agreement with online pharma...

Company

CStone Pharmaceuticals Reduces Ayvakit Price to Boost Accessibility in China

Fineline Cube Apr 11, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced a lower recommended price for its precision medicine...

Company Deals

Hangzhou Baikai Biomedical and Leads Biolabs Partner to Develop Innovative ADCs

Fineline Cube Apr 11, 2023

China-based Hangzhou Baikai Biomedical Co., Ltd and Leads Biolabs Inc. have announced a partnership aimed...

Hospital Policy / Regulatory

NHC Report: Performance Assessment of National Class 2 Public Hospitals in 2021

Fineline Cube Apr 11, 2023

The National Health Commission (NHC) has released the “Report on the National Monitoring and Analysis...

Company Deals

Cuban-Chinese Biotechnology Center Showcases Drug and Vaccine Progress to Cuban Delegation

Fineline Cube Apr 11, 2023

Researchers from Cuba and China at the Yongzhou joint biotechnology innovation center in China’s Hunan...

Medical Device Policy / Regulatory

Hebei Leads Sanming Alliance in Launching 8th VBP for 19 Medical Consumables

Fineline Cube Apr 11, 2023

The Hebei medical drug and device centralized procurement center has announced the start of the...

Company Drug

Takeda Pharma’s Iclusig Poised for Priority Review by CDE for Leukemia Treatments

Fineline Cube Apr 11, 2023

The Center for Drug Evaluation (CDE) website has indicated that Takeda Pharma’s (TYO: 4502) Iclusig...

Company Deals

Arctic Vision Partners with Sinopharm Group for Ophthalmic Product Distribution in China

Fineline Cube Apr 11, 2023

China-based ophthalmology specialist Arctic Vision has entered into a strategic partnership with Sinopharm Group Distribution...

Drug Policy / Regulatory

FDA Issues Complete Response Letters to Six Novel Drugs in Q1 2023

Fineline Cube Apr 10, 2023

According to an analysis, the US FDA issued complete response letters (CRLs) to six novel...

Company Deals

Bioyond Robotics Secures $29 Million in Series A and A+ Financing Rounds

Fineline Cube Apr 10, 2023

Bioyond Robotics, a Shanghai-based intelligent automation company, has reportedly raised around RMB 200 million (USD...

Policy / Regulatory

Henan Province Sees 53.6% Price Reduction in Neuro and Peripheral Intervention Consumables Tender

Fineline Cube Apr 10, 2023

The Henan Province Public Resources Trading Center has released a notification regarding the completion of...

Posts pagination

1 … 573 574 575 … 700

Recent updates

  • China’s NMPA Proposes Sweeping Reforms to Medical Device E-Commerce with New Draft Regulations
  • China’s 12th National Drug Procurement Round Attracts 500+ Companies, Targets 7.34 Billion Units
  • HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases
  • Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals
  • China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s NMPA Proposes Sweeping Reforms to Medical Device E-Commerce with New Draft Regulations

Policy / Regulatory

China’s 12th National Drug Procurement Round Attracts 500+ Companies, Targets 7.34 Billion Units

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Company

Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.